Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-01 16:38:24 - browse：8

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

focus

leisure time

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Ohio train derailment: Experts on toxic chemical risks

The Pandemic Treaty must support building strong health systems

With trial win, GSK could get blood cancer drug back on market

Childhood vaccination ad campaign launches in the U.K.

CDC panel: People 65 and older should get a Covid spring booster shot

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Ohio train derailment: Experts on toxic chemical risks

Hepatitis C has a cure — but many Americans still lack access to it

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Bright Health sells Medicare Advantage business to Molina

Ultragenyx gene therapy for rare liver ailment succeeds in late

Alkermes shareholders re

Change Healthcare cyberattack shows risk of industry consolidation

As demand for Covid shots wanes, Moderna seeks its next success

Cholera vaccine supplies dangerously low, outbreaks surging

knowledge

Medicare Advantage isn’t working — for anyone

ASCO: Palliative care found as helpful given virtually as in person

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

STAT Madness 2024: Meet the contenders

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

focus

leisure time

hotspot

explore